Vaccine delivery carriers: Insights and future perspectives

International Journal of Pharmaceutics

Volumn 440, Issue 1, 2013, Pages 27-38

  Correia Pinto, J F ^a,b   Csaba, N ^a,b   Alonso, M J ^a,b  

^a UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^b NONE   (Spain)

Author keywords

Adjuvant; Antigen delivery; Mucosal immunization; Nanocarrier; Nanovaccine

Indexed keywords

CHITOSAN; DRUG CARRIER; HEPATITIS A VACCINE; INFLUENZA VACCINE; LIPOSOME; MIFAMURTIDE; NANOCARRIER; NANOSPHERE; POLYMER; VACCINE; VIROSOME; VIROSOME VACCINE;

ANTIGEN DETECTION; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ANTIGENIC MODULATION; ARTICLE; CLINICAL TRIAL (TOPIC); COST EFFECTIVENESS ANALYSIS; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG STABILITY; EMULSION; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; IMMUNOSTIMULATION; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; VACCINATION;

ANIMALS; ANTIGENS; DRUG DELIVERY SYSTEMS; HUMANS; NANOPARTICLES; VACCINES;

EID: 84871609642     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2012.04.047     Document Type: Article

References (163)

1. M.T. Aguado Future approaches to vaccine development: single-dose vaccines using controlled-release delivery systems Vaccine 11 1993 596 597
2. M.T. Aguado, and P.H. Lambert Controlled-release vaccines-biodegradable polylactide/polyglycolide (PL/PG) microspheres as antigen vehicles Immunobiology 184 1992 113 125
3. P. Aide, C. Dobaño, J. Sacarlal, J.J. Aponte, I. Mandomando, C. Guinovart, Q. Bassat, M. Renom, L. Puyol, E. Macete, E. Herreros, A. Leach, M.-C. Dubois, M.-A. Demoitie, M. Lievens, J. Vekemans, C. Loucq, W.R. Ballou, J. Cohen, and P.L. Alonso Four year immunogenicity of the RTS, S/AS02A malaria vaccine in Mozambican children during a phase IIb trial Vaccine 29 2011 6059 6067
4. E. Allémann, J.C. Leroux, and R. Gurny Polymeric nano- and microparticles for the oral delivery of peptides and peptidomimetics Adv. Drug Deliv. Rev. 34 1998 171 189
5. A.J. Almeida, H.O. Alpar, and M.R.W. Brown Immune response to nasal delivery of antigenically intact tetanus toxoid associated with poly(l-lactic acid) microspheres in rats, rabbits and guinea pigs J. Pharm. Pharmacol. 45 1993 198 203
6. M.J. Alonso, S. Cohen, T.G. Park, R.K. Gupta, G.R. Siber, and R. Langer Determinants of release rate of tetanus vaccine from polyester microspheres Pharm. Res. 10 1993 945 953
7. M.J. Alonso, R.K. Gupta, C. Min, G.R. Siber, and R. Langer Biodegradable microspheres as controlled-release tetanus toxoid delivery systems Vaccine 12 1994 299 306
8. J.G. Altin, and C.R. Parish Liposomal vaccines-targeting the delivery of antigen Methods 40 2006 39 52
9. M. Amidi, S.G. Romeijn, J.C. Verhoef, H.E. Junginger, L. Bungener, A. Huckriede, D.J.A. Crommelin, and W. Jiskoot N-Trimethyl chitosan (TMC) nanoparticles loaded with influenza subunit antigen for intranasal vaccination: biological properties and immunogenicity in a mouse model Vaccine 25 2007 144 153
10. d.S.S. Aparecida, C.R. Zarate-Blades, F.C.d.S. Galetti, I.T. Brandao, A.P. Masson, E.G. Soares, A.P.U. Araujo, and C.L. Silva A subunit vaccine based on biodegradable microspheres carrying rHsp65 protein and KLK protects BALB/c mice against tuberculosis infection Hum. Vaccines 6 2010 1047 1053
11. P. Arbós, M.A. Arangoa, M.A. Campanero, and J.M. Irache Quantification of the bioadhesive properties of protein-coated PVM/MA nanoparticles Int. J. Pharm. 242 2002 129 136
12. Y. Ataman-Onal, S. Munier, A. Ganée, C. Terrat, P.-Y. Durand, N. Battail, F. Martinon, R. Le Grand, M.-H. Charles, T. Delair, and B. Verrier Surfactant-free anionic PLA nanoparticles coated with HIV-1 p24 protein induced enhanced cellular and humoral immune responses in various animal models J. Control. Release 112 2006 175 185
13. M.F. Bachmann, and G.T. Jennings Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns Nat. Rev. Immunol. 10 2010 787 796
14. J. Banchereau, and R.M. Steinman Dendritic cells and the control of immunity Nature 392 1998 245 252
15. S. Basith, B. Manavalan, G. Lee, S.G. Kim, and S. Choi Toll-like receptor modulators: a patent review (2006-2010) Expert. Opin. Ther. Pat. 21 2011 927 944
16. G. Birrenbach, and P.P. Speiser Polymerized micelles and their use as adjuvants in immunology J. Pharm. Sci. 65 1976 1763 1766
17. M.D. Blanco, and M.J. Alonso Development and characterization of protein-loaded poly(lactide-co-glycolide) nanospheres Eur. J. Pharm. Biopharm. 43 1997 287 294
18. V.W. Bramwell, and Y. Perrie Particulate delivery systems for vaccines Crit. Rev. Ther. Drug Carrier Syst. 22 2005 151 214
19. J. Brooking, S.S. Davis, and L. Illum Transport of nanoparticles across the rat nasal mucosa J. Drug Target. 9 2001 267 279
20. P. Calvo, C. Remuñan-López, J.L. Vila-Jato, and M.J. Alonso Chitosan and chitosan/ethylene oxide-propylene oxide block copolymer nanoparticles as novel carriers for proteins and vaccines Pharm. Res. 14 1997 1431 1436
21. A.M. Carcaboso, R.M. Hernandez, M. Igartua, A.R. Gascon, J.E. Rosas, M.E. Patarroyo, and J.L. Pedraz Immune response after oral administration of the encapsulated malaria synthetic peptide SPf66 Int. J. Pharm. 260 2003 273 282
22. J. Casals, and J. Freund Sensitization and antibody formation in monkeys injected with tubercle bacilli in paraffin oil J. Immunol. 36 1939 399 404
23. S. Casares, T.-D. Brumeanu, and T.L. Richie The RTS, S malaria vaccine Vaccine 28 2010 4880 4894
24. D.W.-S. Chu, S.-J. Hwang, F.S. Lim, H.M.L. Oh, P. Thongcharoen, P.-C. Yang, H.L. Bock, M. Dramé, P. Gillard, Y. Hutagalung, H. Tang, Y.L. Teoh, and R.W. Ballou Immunogenicity and tolerability of an AS03A-adjuvanted prepandemic influenza vaccine: a phase III study in a large population of Asian adults Vaccine 27 2009 7428 7435
25. B. Combadiére, and B. Mahé Particle-based vaccines for transcutaneous vaccination Comp. Immunol. Microbiol. Infect. Dis. 31 2008 293 315
26. N. Csaba, P. Caamano, A. Sanchez, F. Dominguez, and M.J. Alonso PLGA:poloxamer and PLGA:poloxamine blend nanoparticles: new carriers for gene delivery Biomacromolecules 6 2005 271 278
27. N. Csaba, M. Garcia-Fuentes, and M.J. Alonso Nanoparticles for nasal vaccination Adv. Drug Deliv. Rev. 61 2009 140 157
28. N. Csaba, L. Gonzalez, A. Sanchez, and M.J. Alonso Design and characterisation of new nanoparticulate polymer blends for drug delivery J. Biomater. Sci. Polym. Ed. 15 2004 1137 1151
29. N. Csaba, A. Sanchez, and M.J. Alonso PLGA:poloxamer and PLGA:poloxamine blend nanostructures as carriers for nasal gene delivery J. Control. Release 113 2006 164 172
30. R. Cubas, S. Zhang, S.K. Kwon, E.M. Sevick-Muraca, M. Li, C.Y. Chen, and Q.Z. Yao Virus-like particle (VLP) lymphatic trafficking and immune response generation after immunization by different routes J. Immunother. 32 2009 118 128
31. K.Y. Dane, C. Nembrini, A.A. Tomei, J.K. Eby, C.P. O'Neil, D. Velluto, M.A. Swartz, L. Inverardi, and J.A. Hubbell Nano-sized drug-loaded micelles deliver payload to lymph node immune cells and prolong allograft survival J. Control. Release 156 2011 154 160
32. S. De Donato, D. Granoff, M. Minutello, G. Lecchi, M. Faccini, M. Agnello, F. Senatore, P. Verweij, B. Fritzell, and A. Podda Safety and immunogenicity of MF59-adjuvanted influenza vaccine in the elderly Vaccine 17 1999 3094 3101
33. I. De Miguel, L. Imbertie, V. Rieumajou, M. Major, R. Kravtzoff, and D. Betbeder Proofs of the structure of lipid coated nanoparticles (SMBV™) used as drug carriers Pharm. Res. 17 2000 817 824
34. M.-L. De Temmerman, J. Rejman, J. Demeester, D.J. Irvine, B. Gander, and S.C. De Smedt Particulate vaccines: on the quest for optimal delivery and immune response Drug Discov. Today 16 2011 569 582
35. A. Debin, R. Kravtzoff, J.V. Santiago, L. Cazales, S. Sperandio, K. Melber, Z. Janowicz, D. Betbeder, and M. Moynier Intranasal immunization with recombinant antigens associated with new cationic particles induces strong mucosal as well as systemic antibody and CTL responses Vaccine 20 2002 2752 2763
36. P. Duewell, U. Kisser, K. Heckelsmiller, S. Hoves, P. Stoitzner, S. Koernig, A.B. Morelli, B.E. Clausen, M. Dauer, A. Eigler, D. Anz, C. Bourquin, E. Maraskovsky, S. Endres, and M. Schnurr ISCOMATRIX adjuvant combines immune activation with antigen delivery to dendritic cells in vivo leading to effective cross-priming of CD8+ T cells J. Immunol. 187 2011 55 63
37. J.H. Eldridge, J.K. Staas, J.A. Meulbroek, T.R. Tice, and R.M. Gilley Biodegradable and biocompatible poly(dl-lactide-co-glycolide) microspheres as an adjuvant for staphylococcal enterotoxin B toxoid which enhances the level of toxin-neutralizing antibodies Infect. Immun. 59 1991 2978 2986
38. S. Esposito, L. Tagliaferri, C. Daleno, A. Valzano, I. Picciolli, F. Tel, G. Prunotto, D. Serra, C. Galeone, A. Plebani, and N. Principi Pandemic influenza A/H1N1 vaccine administered sequentially or simultaneously with seasonal influenza vaccine to HIV-infected children and adolescents Vaccine 29 2011 1677 1682
39. T. Fifis, A. Gamvrellis, B. Crimeen-Irwin, G.A. Pietersz, J. Li, P.L. Mottram, I.F.C. McKenzie, and M. Plebanski Size-dependent immunogenicity: therapeutic and protective properties of nano-vaccines against tumors J. Immunol. 173 2004 3148 3154
40. S. Fischer, C. Foerg, S. Ellenberger, H.P. Merkle, and B. Gander One-step preparation of polyelectrolyte-coated PLGA microparticles and their functionalization with model ligands J. Control. Release 111 2006 135 144
41. S. Fischer, E. Schlosser, M. Mueller, N.mi Csaba, H.P. Merkle, M. Groettrup, and B. Gander Concomitant delivery of a CTL-restricted peptide antigen and CpG ODN by PLGA microparticles induces cellular immune response J. Drug Target. 17 2009 652 661
42. C. Foged, B. Brodin, S. Frokjaer, and A. Sundblad Particle size and surface charge affect particle uptake by human dendritic cells in an in vitro model Int. J. Pharm. 298 2005 315 322
43. C. Fox Squalene emulsions for parenteral vaccine and drug delivery Molecules 14 2009 3286 3312
44. S. Frey, G. Poland, S. Percell, and A. Podda Comparison of the safety, tolerability, and immunogenicity of a MF59-adjuvanted influenza vaccine and a non-adjuvanted influenza vaccine in non-elderly adults Vaccine 21 2003 4234 4237
45. K. Fu, A.M. Klibanov, and R. Langer Protein stability in controlled-release systems Nat. Biotechnol. 18 2000 24 25
46. K. Fu, D.W. Pack, A.M. Klibanov, and R. Langer Visual evidence of acidic environment within degrading poly(lactic-co-glycolic acid) (PLGA) microspheres Pharm. Res. 17 2000 100 106
47. J. Garcia-Sicilia, P. Gillard, A. Carmona, J.C. Tejedor, J. Aristegui, J.M. Merino, U. Behre, A. Caplanusi, T. Vaman, and I. Dieussaert Immunogenicity and safety of AS03-adjuvanted H1N1 pandemic vaccines in children and adolescents Vaccine 29 2011 4353 4361
48. N. Garçon, and M. Van Mechelen Recent clinical experience with vaccines using MPL- and QS-21-containing adjuvant systems Expert Rev. Vaccines 10 2011 471 486
49. M. Garinot, V. Fievez, V. Pourcelle, F. Stoffelbach, R.A. des, L. Plapied, I. Theate, H. Freichels, C. Jerome, J. Marchand-Brynaert, Y.-J. Schneider, and V. Preat PEGylated PLGA-based nanoparticles targeting M cells for oral vaccination J. Control. Release 120 2007 195 204
50. L.R. Geert Unmet needs in modern vaccinology: adjuvants to improve the immune response Vaccine 28 2010 C25 C36
51. M.P. Girard, J.M. Katz, Y. Pervikov, J. Hombach, and J.S. Tam Report of the 7th meeting on Evaluation of Pandemic Influenza Vaccines in Clinical Trials, World Health Organization, Geneva, 17-18 February 2011 Vaccine 29 2011 7579 7586
52. E.L. Giudice, and J.D. Campbell Needle-free vaccine delivery Adv. Drug Deliv. Rev. 58 2006 68 89
53. A.M. Glauert, J.T. Dingle, and J.A. Lucy Action of saponin on biological cell membranes Nature 196 1962 953 955
54. R. Gluck Adjuvant activity of immunopotentiating reconstituted influenza virosomes (IRIVs) Vaccine 17 1999 1782 1787
55. R. Gluck, and I.C. Metcalfe New technology platforms in the development of vaccines for the future Vaccine 20 2002 B10 B16
56. J.M.M. Gomez, N. Csaba, S. Fischer, A. Sichelstiel, T.M. Kundig, B. Gander, and P. Johansen Surface coating of PLGA microparticles with protamine enhances their immunological performance through facilitated phagocytosis J. Control. Release 130 2008 161 167
57. ® AN nanoparticles as an adjuvant for oral immunotherapy with allergens Vaccine 25 2007 5263 5271
58. S. Gómez, C. Gamazo, B.S. Roman, C. Vauthier, M. Ferrer, and J.M. Irache Development of a novel vaccine delivery system based on gantrez nanoparticles J. Nanosci. Nanotechnol. 6 2006 3283 3289
59. G. Gonzalez, A. Lage, T. Crombet, G. Rodriguez, B. Garcia, A. Cuevas, L. Viña, N. Arteaga, and E. Neninger CIMAvax-EGF: a novel therapeutic vaccine for advanced lung cancer Biotecnol. Apl. 26 2009 345 348
60. C. Gorzelanny, B. Pöppelmann, K. Pappelbaum, B.M. Moerschbacher, and S.W. Schneider Human macrophage activation triggered by chitotriosidase- mediated chitin and chitosan degradation Biomaterials 31 2010 8556 8563
61. P.N. Gupta, K. Khatri, A.K. Goyal, N. Mishra, and S.P. Vyas M-cell targeted biodegradable PLGA nanoparticles for oral immunization against hepatitis B J. Drug Target. 15 2007 701 713
62. P.N. Gupta, V. Mishra, A. Rawat, P. Dubey, S. Mahor, S. Jain, D.P. Chatterji, and S.P. Vyas Non-invasive vaccine delivery in transfersomes, niosomes and liposomes: a comparative study Int. J. Pharm. 293 2005 73 82
63. R.K. Gupta, A.-C. Chang, P. Griffin, R. Rivera, and G.R. Siber In vivo distribution of radioactivity in mice after injection of biodegradable polymer microspheres containing 14C-labeled tetanus toxoid Vaccine 14 1996 1412 1416
64. R.K. Gupta, and B.E. Rost Aluminum compounds as vaccine adjuvants Vaccine Adjuvants: Preparation Methods and Research Protocols vol. 42 2000 pp. 65-89
65. I. Gutierro, R.M. Hernández, M. Igartua, A.R. Gascón, and J.L. Pedraz Size dependent immune response after subcutaneous, oral and intranasal administration of BSA loaded nanospheres Vaccine 21 2002 67 77
66. B. Heurtault, B. Frisch, and F. Pons Liposomes as delivery systems for nasal vaccination: strategies and outcomes Expert Opin. Drug Deliv. 7 2010 829 844
67. A.M. Hillery, and A.T. Florence The effect of adsorbed poloxamer 188 and 407 surfactants on the intestinal uptake of 60-nm polystyrene particles after oral administration in the rat Int. J. Pharm. 132 1996 123 130
68. H. HogenEsch Mechanisms of stimulation of the immune response by aluminum adjuvants Vaccine 20 2002 S34 S39
69. K.F. Hu, K. Lövgren-Bengtsson, and B. Morein Immunostimulating complexes (ISCOMs) for nasal vaccination Adv. Drug Deliv. Rev. 51 2001 149 159
70. M. Igartua, R.M. Hernández, A. Esquisabel, A.R. Gascón, M.B. Calvo, and J.L. Pedraz Enhanced immune response after subcutaneous and oral immunization with biodegradable PLGA microspheres J. Control. Release 56 1998 63 73
71. P. Johansen, Y. Men, H.P. Merkle, and B. Gander Revisiting PLA/PLGA microspheres: an analysis of their potential in parenteral vaccination Eur. J. Pharm. Biopharm. 50 2000 129 146
72. J. Kazzaz, M. Singh, M. Ugozzoli, J. Chesko, E. Soenawan, and D.T. O'Hagan Encapsulation of the immune potentiators MPL and RC529 in PLG microparticles enhances their potency J. Control. Release 110 2006 566 573
73. E. Kedar, H. Gur, I. Babai, S. Samira, S. Even-Chen, and Y. Barenholz Delivery of cytokines by liposomes: hematopoietic and immunomodulatory activity of interleukin-2 encapsulated in conventional liposomes and in long-circulating liposomes J. Immunother. 23 2000 131 145
74. R.A. Kenley, M.O. Lee, T.R. Mahoney, and L.M. Sanders Poly(lactide-co-glycolide) decomposition kinetics in vivo and in vitro Macromolecules 20 1987 2398 2403
75. R.T. Kenney, S.A. Frech, L.R. Muenz, C.P. Villar, and G.M. Glenn Dose sparing with intradermal injection of influenza vaccine N. Engl. J. Med. 351 2004 2295 2301
76. C.R. Kensil QS-21 adjuvant Vaccine Adjuvants: Preparation Methods and Research Protocols vol. 42 2000 pp. 259-271
77. T. Kissel, X.L. Y, C. Volland, S. Gorich, and R. Koneberg Parenteral protein delivery systems using biodegradable polyesters of ABA block structure, containing hydrophobic poly(lactide-co-glycolide) A blocks and hydrophilic poly(ethylene oxide) B blocks J. Control. Release 39 1996 315 326
78. M. Kovacsovics-Bankowski, K. Clark, B. Benacerraf, and K.L. Rock Efficient major histocompatibility complex class I presentation of exogenous antigen upon phagocytosis by macrophages Proc. Natl. Acad. Sci. U. S. A. 90 1993 4942 4946
79. R.A. Lake, and B.W.S. Robinson Immunotherapy and chemotherapy-a practical partnership Nat. Rev. Cancer 5 2005 397 405
80. M. Larche, and D.C. Wraith Peptide-based therapeutic vaccines for allergic and autoimmune diseases Nat. Med. 11 2005 S69 S76
81. R.C. Layton, N. Petrovsky, A.P. Gigliotti, Z. Pollock, J. Knight, N. Donart, J. Pyles, K.S. Harrod, P. Gao, and F. Koster Delta inulin polysaccharide adjuvant enhances the ability of split-virion H5N1 vaccine to protect against lethal challenge in ferrets Vaccine 29 2011 6242 6251
82. N. Leffers, A.J.A. Lambeck, M.J.M. Gooden, B.-N. Hoogeboom, R. Wolf, I.E. Hamming, B.G. Hepkema, P.H.B. Willemse, B.H.W. Molmans, H. Hollema, J.W. Drijfhout, W.J. Sluiter, A.R.P.M. Valentijn, L.M. Fathers, J. Oostendorp, A.G.J. van der Zee, C.J. Melief, S.H. van der Burg, T. Daemen, and H.W. Nijman Immunization with a P53 synthetic long peptide vaccine induces P53-specific immune responses in ovarian cancer patients, a phase II trial Int. J. Cancer 125 2009 2104 2113
83. I. Leroux-Roels, M. Koutsoukos, F. Clement, S. Steyaert, M. Janssens, P. Bourguignon, K. Cohen, M. Altfeld, P. Vandepapelière, L. Pedneault, L. McNally, G. Leroux-Roels, and G. Voss Strong and persistent CD4+ T-cell response in healthy adults immunized with a candidate HIV-1 vaccine containing gp120, Nef and Tat antigens formulated in three adjuvant systems Vaccine 28 2010 7016 7024
84. I. Leroux-Roels, G. Leroux-Roels, O. Ofori-Anyinam, P. Moris, E. De Kock, F. Clement, M.-C. Dubois, M. Koutsoukos, M.-A. Demoitie, J. Cohen, and W.R. Ballou Evaluation of the safety and immunogenicity of two antigen concentrations of the Mtb72F/AS02A candidate tuberculosis vaccine in purified protein derivative-negative adults Clin. Vaccine Immunol. 17 2010 1763 1771
85. L. Leserman Liposomes as protein carriers in immunology J. Liposome Res. 14 2004 175 189
86. N. Li, L.-H. Peng, X. Chen, S. Nakagawa, and J.-Q. Gao Transcutaneous vaccines: novel advances in technology and delivery for overcoming the barriers Vaccine 29 2011 6179 6190
87. N. Li, L. Peng, X. Chen, S. Nakagawa, and J. Gao Effective transcutaneous immunization by antigen-loaded flexible liposome in vivo Int. J. Nanomed. 6 2011 3241 3250
88. E.B. Lindblad Safety evaluation of vaccine adjuvants Vaccine Adjuvants and Delivery Systems 2006 pp. 421-444
89. K. Lovgren, and B. Morein The requirement of lipids for the formation of immunostimulating complexes (iscoms) Biotechnol. Appl. Biochem. 10 1988 161 172
90. B. Mahe, A. Vogt, C. Liard, D. Duffy, V. Abadie, O. Bonduelle, A. Boissonnas, W. Sterry, B. Verrier, U. Blume-Peytavi, and B. Combadiere Nanoparticle-based targeting of vaccine compounds to skin antigen-presenting cells by hair follicles and their transport in mice J. Invest. Dermatol. 129 2008 1156 1164
91. M. Manning, D. Chou, B. Murphy, R. Payne, and D. Katayama Stability of protein pharmaceuticals: an update Pharm. Res. 27 2009 544 575
92. V. Manolova, A. Flace, M. Bauer, K. Schwarz, P. Saudan, and M.F. Bachmann Nanoparticles target distinct dendritic cell populations according to their size Eur. J. Immunol. 38 2008 1404 1413
93. C. Marchand, J. Bachand, J. Périnêt, E. Baraghis, M. Lamarre, G.E. Rivard, G. De Crescenzo, and C.D. Hoemann C3, C5, and factor B bind to chitosan without complement activation J. Biomed. Mater. Res. A 93A 2009 1429 1441
94. P. Marrack, A.S. McKee, and M.W. Munks Towards an understanding of the adjuvant action of aluminium Nat. Rev. Immunol. 9 2009 287 293
95. E. Mata, M. Igartua, M.E. Patarroyo, J.L. Pedraz, and R.M. Hernandez Enhancing immunogenicity to PLGA microparticulate systems by incorporation of alginate and RGD-modified alginate Eur. J. Pharm. Sci. 44 2011 32 40
96. P. Matzinger Tolerance, danger, and the extended family Annu. Rev. Immunol. 12 1994 991 1045
97. Y. Men, C. Thomasin, H.P. Merkle, B. Gander, and G. Corradin A single administration of tetanus toxoid in biodegradable microspheres elicits T cell and antibody responses similar or superior to those obtained with aluminum hydroxide Vaccine 13 1995 683 689
98. S.M. Moghimi, A.E. Hawley, N.M. Christy, T. Gray, L. Illum, and S.S. Davis Surface engineered nanospheres with enhanced drainage into lymphatics and uptake by macrophages of the regional lymph nodes FEBS Lett. 344 1994 25 30
99. J.J. Moon, H. Suh, M.E. Polhemus, C.F. Ockenhouse, A. Yadava, and D.J. Irvine Antigen-displaying lipid-enveloped PLGA nanoparticles as delivery agents for a Plasmodium vivax malaria vaccine PLoS ONE 7 2012 e31472
100. S. Morel, A. Didierlaurent, P. Bourguignon, S. Delhaye, B. Baras, V. Jacob, C. Planty, A. Elouahabi, P. Harvengt, H. Carlsen, A. Kielland, P. Chomez, N. Garçon, and M. Van Mechelen Adjuvant System AS03 containing [alpha]-tocopherol modulates innate immune response and leads to improved adaptive immunity Vaccine 29 2011 2461 2473
101. M. Moser, and O. Leo Key concepts in immunology Vaccine 28 2010 C2 C13
102. M. Murillo, C. Gamazo, J.M. Irache, and M.M. Goñi Polyester microparticles as a vaccine delivery system for brucellosis: influence of the polymer on release, phagocytosis and toxicity J. Drug Target. 10 2002 211 219
103. M.R. Neutra, and P.A. Kozlowski Mucosal vaccines: the promise and the challenge Nat. Rev. Immunol. 6 2006 148 158
104. K. Nishimura, S.-i. Nishimura, N. Nishi, F. Numata, Y. Tone, S. Tokura, and I. Azuma Adjuvant activity of chitin derivatives in mice and guinea-pigs Vaccine 3 1985 379 384
105. D.T. O'Hagan, and M. Singh Microparticles as vaccine adjuvants and delivery systems Expert Rev. Vaccines 2 2003 269 283
106. G. Ott, G.L. Barchfeld, D. Chernoff, R. Radhakrishnan, H.P. van, and N.G. Van MF59: design and evaluation of a safe and potent adjuvant for human vaccines Pharm. Biotechnol. 6 1995 277 296
107. G. Ott, R. Radhakrishnan, J.H. Fang, and M. Hora The adjuvant MF59: a 10-year perspective Methods Mol. Med. 42 2000 211 228
108. M.O. Oyewumi, A. Kumar, and Z. Cui Nano-microparticles as immune adjuvants: correlating particle sizes and the resultant immune responses Expert Rev. Vaccines 9 2010 1095 1107
109. P. Paolicelli, C. Prego, A. Sanchez, and M.J. Alonso Surface-modified PLGA-based nanoparticles that can efficiently associate and deliver virus-like particles Nanomedicine 5 2010 843 853
110. A. Pashine, N.M. Valiante, and J.B. Ulmer Targeting the innate immune response with improved vaccine adjuvants Nat. Med. 11 2005 S63 S68
111. R. Pawar, A. Ben-Ari, and A.J. Domb Protein and peptide parenteral controlled delivery Expert Opin. Biol. Ther. 4 2004 1203 1212
112. ® adjuvant for antigen delivery Adv. Drug Deliv. Rev. 57 2005 465 474
113. L.J. Peek, C.R. Middaugh, and C. Berkland Nanotechnology in vaccine delivery Adv. Drug Deliv. Rev. 60 2008 915 928
114. D.H. Persing, R.N. Coler, M.J. Lacy, D.A. Johnson, J.R. Baldridge, R.M. Hershberg, and S.G. Reed Taking toll: lipid A mimetics as adjuvants and immunomodulators Trends Microbiol. 10 2002 s32 s37
115. C. Prego, P. Paolicelli, B. Diaz, S. Vicente, A. Sánchez, Á. Gonzalez-Fernández, and M.J. Alonso Chitosan-based nanoparticles for improving immunization against hepatitis B infection Vaccine 28 2010 2607 2614
116. I. Preis, and R.S. Langer A single-step immunization by sustained antigen release J. Immunol. Methods 28 1979 193 197
117. R. Ramya, P.C. Verma, V.K. Chaturvedi, P.K. Gupta, K.D. Pandey, M. Madhanmohan, T.R. Kannaki, R. Sridevi, and B. Anukumar Poly(lactide-co- glycolide) microspheres: a potent oral delivery system to elicit systemic immune response against inactivated rabies virus Vaccine 27 2009 2138 2143
118. M. Rao, S.W. Rothwell, N.M. Wassef, R.E. Pagano, and C.R. Alving Visualization of peptides derived from liposome-encapsulated proteins in the trans-Golgi area of macrophages Immunol. Lett. 59 1997 99 105
119. S.T. Reddy, A.J. van der Vlies, E. Simeoni, V. Angeli, G.J. Randolph, C.P. O'Neil, L.K. Lee, M.A. Swartz, and J.A. Hubbell Exploiting lymphatic transport and complement activation in nanoparticle vaccines Nat. Biotechnol. 25 2007 1159 1164
120. S.G. Reed, S. Bertholet, R.N. Coler, and M. Friede New horizons in adjuvants for vaccine development Trends Immunol. 30 2009 23 32
121. M.A. Rezaei, and M.J. Alonso Preparation and evaluation of chitosan nanoparticles containing diphtheria toxoid as new carriers for nasal vaccine delivery in mice Arch. Razi Inst. 61 2006 13 25
122. F. Roman, T. Vaman, B. Gerlach, A. Markendorf, P. Gillard, and J.-M. Devaster Immunogenicity and safety in adults of one dose of influenza A H1N1v 2009 vaccine formulated with and without AS03A-adjuvant: preliminary report of an observer-blind, randomised trial Vaccine 28 2010 1740 1745
123. V. Saini, V. Jain, M.S. Sudheesh, K.S. Jaganathan, P.K. Murthy, and D.V. Kohli Comparison of humoral and cell-mediated immune responses to cationic PLGA microspheres containing recombinant hepatitis B antigen Int. J. Pharm. 408 2011 50 57
124. A. Sanchez, R.K. Gupta, M.J. Alonso, G.R. Siber, and R. Langer Pulsed controlled-release system for potential use in vaccine delivery J. Pharm. Sci. 85 1996 547 552
125. J.P.Y. Scheerlinck, and D.L.V. Greenwood Virus-sized vaccine delivery systems Drug Discov. Today 13 2008 882 887
126. M. Schnurr, Q. Chen, A. Shin, W. Chen, T. Toy, C. Jenderek, S. Green, L. Miloradovic, D. Drane, I.D. Davis, J. Villadangos, K. Shortman, E. Maraskovsky, and J. Cebon Tumor antigen processing and presentation depend critically on dendritic cell type and the mode of antigen delivery Blood 105 2005 2465 2472
127. V. Schultze, V. D'Agosto, A. Wack, D. Novicki, J. Zorn, and R. Hennig Safety of MF59(TM) adjuvant Vaccine 26 2008 3209 3222
128. ®, 2011. Chemical Abstracts Service: Columbus, OH, 2011 RN 58-08-2 (accessed 10.10.11).
129. M. Shakweh, G. Ponchel, and E. Fattal Particle uptake by Peyer's patches: a pathway for drug and vaccine delivery Expert Opin. Drug Deliv. 1 2004 141 163
130. F.A. Sharp, D. Ruane, B. Claass, E. Creagh, J. Harris, P. Malyala, M. Singh, D.T. O'Hagan, V. Pétrilli, J. Tschopp, L.A.J. O'Neill, and E.C. Lavelle Uptake of particulate vaccine adjuvants by dendritic cells activates the NALP3 inflammasome Proc. Natl. Acad. Sci. U. S. A. 106 2009 870 875
131. ® formulations in animal and primate models Vaccine 19 2001 2661 2665
132. C.D. Skene, and P. Sutton Saponin-adjuvanted particulate vaccines for clinical use Methods 40 2006 53 59
133. B. Sluetter, L. Plapied, V. Fievez, M. Alonso-Sande, R.A. des, Y.-J. Schneider, R.E. Van, W. Jiskoot, and V. Preat Mechanistic study of the adjuvant effect of biodegradable nanoparticles in mucosal vaccination J. Control. Release 138 2009 113 121
134. J. Smith, R. Leke, A. Adams, and R.H. Tangermann Certification of polio eradication: process and lessons learned Bull. World Health Organ. 82 2004 24 30
135. G.D. Sprott, C.J. Dicaire, K. Gurnani, L.A. Deschatelets, and L. Krishnan Liposome adjuvants prepared from the total polar lipids of Haloferax volcanii, Planococcus spp. and Bacillus firmus differ in ability to elicit and sustain immune responses Vaccine 22 2004 2154 2162
136. I. Stephenson, M.C. Zambon, A. Rudin, A. Colegate, A. Podda, R. Bugarini, G.d. Giudice, A. Minutello, S. Bonnington, J. Holmgren, K.H.G. Mills, and K.G. Nicholson Phase I evaluation of intranasal trivalent inactivated influenza vaccine with nontoxigenic Escherichia coli enterotoxin and novel biovector as mucosal adjuvants, using adult volunteers J. Virol. 80 2006 4962 4970
137. C.H. Stuart-Harris Adjuvant influenza vaccines Bull. World Health Organ. 41 1969 617 621
138. M.A. Swartz The physiology of the lymphatic system Adv. Drug Deliv. Rev. 50 2001 3 20
139. I. Tamayo, J.M. Irache, C. Mansilla, J. Ochoa-Reparaz, J.J. Lasarte, and C. Gamazo Poly(anhydride) nanoparticles act as active Th1 adjuvants through Toll-like receptor exploitation Clin. Vaccine Immunol. 17 2010 1356 1362
140. L. Thiele, H.P. Merkle, and E. Walter Phagocytosis and phagosomal fate of surface-modified microparticles in dendritic cells and macrophages Pharm. Res. 20 2003 221 228
141. M. Tobío, and M.J. Alonso Study of the inactivation process of the tetanus toxoid in contact with poly(lactic/glycolic acid) degrading microspheres S.T.P. Pharma Sci. 8 1998 303 310
142. M. Tobío, R. Gref, A. Sanchez, R. Langer, and M.J. Alonso Stealth PLA-PEG nanoparticles as protein carriers for nasal administration Pharm. Res. 15 1998 270 275
143. M. Tobío, J. Nolley, Y. Guo, J. McIver, and M. José Alonso A novel system based on a poloxamer/PLGA blend as a tetanus toxoid delivery vehicle Pharm. Res. 16 1999 682 688
144. M. Tobío, A. Sánchez, A. Vila, I. Soriano, C. Evora, J.L. Vila-Jato, and M.J. Alonso The role of PEG on the stability in digestive fluids and in vivo fate of PEG-PLA nanoparticles following oral administration Colloids Surf., B 18 2000 315 323
145. V. Usonis, V. Bakasenas, R. Valentelis, G. Katiliene, D. Vidzeniene, and C. Herzog Antibody titres after primary and booster vaccination of infants and young children with a virosomal hepatitis A vaccine (Epaxal) Vaccine 21 2003 4588 4592
146. R.J. Verheul, B. Sluetter, S.M. Bal, J.A. Bouwstra, W. Jiskoot, and W.E. Hennink Covalently stabilized trimethyl chitosan-hyaluronic acid nanoparticles for nasal and intradermal vaccination J. Control. Release 156 2011 46 52
147. Vicente, S., Díaz-Freitas, Belén, Sánchez, Alejandro, González-Fernández, África, Alonso, M.J., 2010. Adjuvant formulations based on polysaccharidic nanocapsules as potential single-dose vaccines. 6th Annual Grand Challenges in Global Health Conference, Seattle,US.
148. S. Vicente, B. Díaz, A. Sánchez, A. González- Fernández, and M.J. Alonso Polysaccharide-based Nanocapsules as Vehicles for Nasal Immunization Against Hepatitis B 2009 2nd Pharm. Sci. Fair Nice, France
149. A. Vila, H. Gill, O. McCallion, and M.J. Alonso Transport of PLA-PEG particles across the nasal mucosa: effect of particle size and PEG coating density J. Control. Release 98 2004 231 244
150. A. Vila, A. Sanchez, C. Evora, I. Soriano, J.J.L. Vila, and M.J. Alonso PEG-PLA nanoparticles as carriers for nasal vaccine delivery J. Aerosol Med. 17 2004 174 185
151. A. Vila, A. Sánchez, K. Janes, I. Behrens, T. Kissel, J.L.V. Jato, and M.J. Alonso Low molecular weight chitosan nanoparticles as new carriers for nasal vaccine delivery in mice Eur. J. Pharm. Sci. 57 2004 123 131
152. A. Vila, A. Sánchez, M. Tobío, P. Calvo, and M.J. Alonso Design of biodegradable particles for protein delivery J. Control. Release 78 2002 15 24
153. E.N. Vinageras, A. de la Torre, M.O. Rodríguez, M.C. Ferrer, I. Bravo, M.M. del Pino, D.A. Abreu, S.A. Brooks, R. Rives, C. del Castillo Carrillo, M.G. Dueñas, C. Viada, B.G. Verdecia, T.C. Ramos, G.G. Marinello, and A.L. Dávila Phase II randomized controlled trial of an epidermal growth factor vaccine in advanced non-small-cell lung cancer J. Clin. Oncol. 26 2008 1452 1458
154. F.R. Vogel Improving vaccine performance with adjuvants Clin. Infect. Dis. 30 2000 S266 S270
155. A. Vogt, B. Combadiere, S. Hadam, K.M. Stieler, J. Lademann, H. Schaefer, B. Autran, W. Sterry, and U. Blume-Peytavi 40 nm, but not 750 or 1500 nm, nanoparticles enter epidermal CD1a+ cells after transcutaneous application on human skin J. Invest. Dermatol. 126 2006 1316 1322
156. A. Wack, and R. Rappuoli Vaccinology at the beginning of the 21st century Curr. Opin. Immunol. 17 2005 411 418
157. D.C. Waite, E.W. Jacobson, F.A. Ennis, R. Edelman, B. White, R. Kammer, C. Anderson, and C.R. Kensil Three double-blind, randomized trials evaluating the safety and tolerance of different formulations of the saponin adjuvant QS-21 Vaccine 19 2001 3957 3967
158. D.L. Wise, D.J. Trantolo, R.T. Marino, and J.P. Kitchell Opportunities and challenges in the design of implantable biodegradable polymeric systems for the delivery of antimicrobial agents and vaccines Adv. Drug Deliv. Rev. 1 1987 19 40
159. Y. Wu, R.D. Ellis, D. Shaffer, E. Fontes, E.M. Malkin, S. Mahanty, M.P. Fay, D. Narum, K. Rausch, A.P. Miles, J. Aebig, A. Orcutt, O. Muratova, G. Song, L. Lambert, D. Zhu, K. Miura, C. Long, A. Saul, L.H. Miller, and A.P. Durbin Phase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated with montanide ISA 51 PLoS ONE 3 2008 e2636
160. www.clinicaltrials.gov, 2011. Last visited at October 2011. US National Institutes of Health.
161. M.I. Zapata, G.E. Peck, S.L. Hem, J.L. White, and J.R. Feldkamp Mechanism of freeze-thaw instability of aluminum hydroxycarbonate and magnesium hydroxide gels J. Pharm. Sci. 73 1984 3 8
162. J.A. Zasadzinski, B. Wong, N. Forbes, G. Braun, and G. Wu Novel methods of enhanced retention in and rapid, targeted release from liposomes Curr. Opin. Colloid Interface Sci. 16 2011 203 214
163. F. Zepp Principles of vaccine design-lessons from nature Vaccine 28 2010 C14 C24